Portal Hypertension and Cirrhosis: How Baveno VII Reframed the Diagnosis

Portal hypertension is the rising pressure in the venous system that carries blood from the gut through the liver, and in cirrhosis it drives the complications that make the disease dangerous: varices that can bleed, fluid that collects in the abdomen, and episodes of confusion. For decades the only definitive way to measure that pressure was to thread a catheter into a hepatic vein. The 2022 Baveno VII consensus, published in the Journal of Hepatology by Roberto de Franchis and the Baveno VII Faculty, changed the entry point. It formalized a way to rule clinically significant portal hypertension in or out using two numbers most patients already have, liver stiffness measured by elastography and the platelet count, rather than a catheter reading.

The pressure that was hard to measure

The reference standard for portal pressure is the hepatic venous pressure gradient, or HVPG, the difference between the pressure in a wedged and a free hepatic vein. Baveno VII defines clinically significant portal hypertension as an HVPG of 10 mmHg or higher, the level above which the risk of developing varices, of a first decompensating event, and of liver-related death begins to climb. The problem is practical. Measuring HVPG requires transjugular catheterization at a specialized center, so the great majority of people with chronic liver disease never had the test, and clinicians were left estimating risk indirectly.

A new name for a continuum

Baveno VII also leans into a vocabulary shift that its predecessor introduced: it favors "compensated advanced chronic liver disease," or cACLD, over "compensated cirrhosis." The reasoning is that severe fibrosis and early cirrhosis sit on a continuum that cannot be cleanly separated at the bedside, and often not even on biopsy. What matters for a patient is the risk of portal hypertension and decompensation, not the exact histological label. The consensus sets stiffness thresholds for this: a liver stiffness measurement of 10 kPa or below by transient elastography effectively rules out cACLD, a value between 10 and 15 kPa is suggestive, and a value above 15 kPa is highly suggestive.

The rule of five

To make the numbers memorable, Baveno VII proposes a "rule of five" for liver stiffness by transient elastography: 10, 15, 20, and 25 kPa mark rungs of progressively higher relative risk of decompensation and liver-related death. The mnemonic is deliberately simple because it is meant to be used at the point of care, translating a single elastography value into a rough prognostic tier without any calculation. A patient at 12 kPa and a patient at 24 kPa are both, technically, in the same broad category of advanced liver disease, yet the consensus makes clear their near-term risk is not the same.

Ruling portal hypertension in and out

The core of the reframing is a pair of noninvasive rules. A liver stiffness of 15 kPa or lower combined with a platelet count of at least 150 x 10^9/L rules clinically significant portal hypertension out, with sensitivity and negative predictive value above 90 percent. At the other end, a liver stiffness of 25 kPa or higher is enough to rule it in, with specificity and positive predictive value above 90 percent. Baveno VII fills in part of the middle with combination criteria, for example a stiffness of 20 to 25 kPa with platelets under 150, or 15 to 20 kPa with platelets under 110, which also point toward significant portal hypertension.

That still leaves a grey zone. Many patients land between the confident rule-out and rule-in bands, and for them a single elastography reading is not the end of the workup. Baveno VII positions additional tools, including spleen stiffness measurement and, where it is available and would change management, the HVPG itself, as ways to resolve the intermediate cases rather than defaulting everyone to an invasive test.

The endoscopy some patients can skip

The same two numbers feed a related decision that Baveno VII carries forward from Baveno VI. Patients whose liver stiffness is under 20 kPa and whose platelet count is above 150,000 have a low enough probability of high-risk varices that screening endoscopy can reasonably be deferred and simply repeated over time. That criterion spares a share of patients an invasive look they were unlikely to benefit from, which is part of why the framework was adopted so widely.

What the reframe changes, and what it does not

The practical effect is a shift in where the decision happens. Risk stratification that once depended on a procedure available in a handful of centers now starts with an elastography probe and a routine blood count, which brings it within reach of far more clinics. The limits deserve equal attention, though. Validation work, including a 2025 individual patient data meta-analysis in the Journal of Hepatology, confirms that the rule-in and rule-out thresholds hold up against HVPG, while also showing that their accuracy falls in people with obesity and in metabolic dysfunction-associated steatotic liver disease, prompting proposed refinements for those groups. The criteria sort patients into risk categories; they do not by themselves prescribe treatment, and the choice of whether and how to prevent decompensation remains an individualized clinical judgment. This article is educational and is not medical advice.